vasospasm. Other cerebrovascular vasospasm and vasoconstriction
Conditions
Interventions
Intervention 1: Intervention group: Memantine (manufactured by Subhan Co.) 10 mg (2 tablets of 5 mg), twice a day, for 7 days. Intervention 2: Control group: Plasboza, according to appearance characte
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age above 18 years Visit within the first 24 hours of the onset of symptoms Confirmation of subarachnoid hemorrhage by the plan's neurosurgeon (based on history, clinical findings and CT scan or brain MRI) Patients with consciousness level 9 to 15 Consent of the patient or her legal guardian (in case of consciousness disorder) to participate in the study
Exclusion criteria
Exclusion criteria: Lack of patient consent to participate in the study Patients with a history of SAH or cerebral infarction Patients diagnosed with hydrocephalus Patients with secondary cerebral hemorrhage History of allergy to memantine Kidney failure stage 4 or 5 based on Acute Kidney Injury Network criteria (27) Moderate to severe liver disease (Child-Pugh criteria, grade B and C) (28) Having a history of epilepsy History of dementia The patient has a history of taking memantine in the last 6 months of pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| GCS. Timepoint: After surgery for 1 week. Method of measurement: Visual analog scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Vasospasm. Timepoint: Before surgery and 1 week after surgery. Method of measurement: angiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMisagh Shafizad
Mazandaran University of Medical Sciences
Outcome results
None listed